StockLens

Sun Pharmaceutical Industries Limited (SUNPHARMA) share price and analysis

SUNPHARMA last traded at ₹1,870.00 (+0.13%) on the NSE. Market cap ₹4,48,676 Cr (Large cap), Pharma & Healthcare sector.

Overall rating: 6.4/10 (Average)

Long-term view: Good for long-term. More strengths than weaknesses for a multi-year hold. Trade bias (next few weeks): Strong long. Trend and momentum are clearly pointing up.

Strengths of SUNPHARMA

Weaknesses of SUNPHARMA

Key numbers

NumberValueAssessmentNormal range
P/E (TTM)40.9In line with peers37.0–49.3 (sector median 41.1)
Forward P/E29.8Profits expected to growbelow today's P/E (40.9) and near 41
Price / book5.02Normal2–6
EPS (TTM)₹45.70Profitableabove ₹0
Return on equity13.1%Average15%+ (below 10% is weak)
Debt / equity0.04Low debtbelow 1.0 (under 0.5 is great)
Net margin17.8%Healthy10%+ (below 5% is thin)
Operating margin23.3%Strong20%+ strong, below 10% thin
Revenue growth+11.9%Growing well10%+ a year (below 3% is weak)
Profit growth-36.2%Falling10%+ a year (falling is weak)
Dividend yield0.86%Small payout1.5%+ (none is fine for growth firms)
Current ratio2.94Comfortable1.5+ (below 1 is tight)
52W high₹2,046.909% below · near the highprice in the top 40% of its 52-week range
52W low₹1,583.70Price is 18% above it
50-DMA₹1,818.71Price 2.8% aboveprice above it = short-term uptrend
200-DMA₹1,817.61Price 2.9% aboveprice above it = long-term uptrend
1Y return+10.1%Beat the Nifty 50Nifty 50 did −0.4%
Beta0.13Steadier than the market0.8–1.3 (1 = moves with market)
Promoter / insider55.6%Owners have a big stake50%+ shows owner commitment
Institutions30.3%Strong big-investor interest30%+ is strong
Analyst target₹2,111.9412.9% upside · 33 analysts8%+ upside

Questions about SUNPHARMA

What is the share price of Sun Pharmaceutical Industries Limited (SUNPHARMA) today?

SUNPHARMA last traded at ₹1,870.00 (+0.13% on the day) on the NSE. Its 52-week range is ₹1,583.70 to ₹2,046.90. Prices are delayed and come from Yahoo Finance.

Is SUNPHARMA a good stock for the long term?

StockLens rates SUNPHARMA 6.4 out of 10 (Average) overall. Its long-term verdict is "Good for long-term": More strengths than weaknesses for a multi-year hold. Strengths: low debt, uptrend, strong momentum. Concerns: falling profits, lagging the market.

Is SUNPHARMA share overvalued?

SUNPHARMA trades at a P/E of 40.9 against a Pharma & Healthcare median of 41.1, which StockLens rates as "In line with peers". Its price-to-book ratio is 5.02.

Is SUNPHARMA good for short-term trading?

The trade bias for the next few weeks is "Strong long": Trend and momentum are clearly pointing up. The price is 2.9% above its 200-day average and 14-day RSI is 62.

Which stocks are similar to SUNPHARMA?

Similar Pharma & Healthcare stocks of comparable size include Divi's Laboratories, Torrent Pharmaceuticals, Laurus Labs, Apollo Hospitals, Zydus Lifesciences. You can compare up to 4 of them side by side on StockLens.

About Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, ophthalmology, urology, dermatology, respiratory, anti-infectives, oncology, psychiatry, neurology, orthopaedic, nephrology, dental, and nutritionals. It also provides generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; specialty medications; antiretrovirals medications; and over-the-counter products, such as vitamins, analgesics, digestives, and lifestyle. In addition, the company offers generics and APIs for anti-cancers, peptides, steroids, sex hormones, immunosuppressant drugs, and controlled substances. Sun Pharmaceutical Industries Limited was founded in 1983 and is headquartered in Mumbai, India.

Stocks similar to SUNPHARMA

Compare SUNPHARMA with DIVISLAB, TORNTPHARM, LAURUSLABS

Educational information, not investment advice. Data from Yahoo Finance and NSE Indices; prices may be delayed.